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Abstract
Introduction Growing evidence of the teratogenic potential of sodium valproate (VPA) has changed prescribing practices 
across the globe; however, the impact of this research and the consequent dissemination of a Dear Health Care Professional 
Letter (DHCPL) in December 2015, recommending avoidance of the teratogen VPA in women of childbearing age (WOCBA) 
and pregnant women in South Africa, is unknown. We explored trends and reasons for VPA use among pregnant women and 
WOCBA in the public sector in Western Cape Province from 1 January 2015 to 31 December 2017.
Methods Using the provincial health information exchange that collates routine electronic health data via unique patient 
identifiers, we analysed clinical and pharmacy records from 2015 to 2017 to determine prescription patterns of VPA and 
other antiepileptic drug (AED) and mood-stabilising medicine (MSM) use in WOCBA and pregnant women. Senior clini-
cians and policy makers were consulted to understand the determinants of VPA use.
Results At least one VPA prescription was dispensed to between 8205 (0.79%) and 9425 (0.94%) WOBCA from a cohort 
of approximately 1 million WOCBA attending provincial health care facilities per year. Prescriptions were more likely in 
HIV-infected women compared with HIV-uninfected women (1.1–1.3% vs. 0.7–0.9%; p < 0.001). VPA use in WOCBA 
remained stable at 0.8–0.9% over the review period despite the 2016 DHCPL. VPA was the most prescribed AED/MSM, 
constituting 43.2–45.5% of all WOCBA taking at least one such agent, while lamotrigine, the other recommended first-line 
agent, was only prescribed in 7.8–8.9% of WOCBA. Over 3 years, approximately 663 pregnancies were exposed to VPA, 
with a steady rise in the number of exposures each year (n = 204, 214 and 245, respectively).
Conclusion Despite warnings, VPA remained the most frequently prescribed AED or MSM in WOCBA. Contributing fac-
tors are described.
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article (https ://doi.org/10.1007/s4026 4-020-00987 -4) contains 
supplementary material, which is available to authorized users.
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1 Introduction
In recent years, the Medicines Control Council in South 
Africa (MCC; now known as the South African Health Prod-
ucts Regulatory Authority [SAHPRA]), the US Food and 
Drug Administration (FDA) [1], the European Medicines 
Agency (EMA) [2] and other regulatory authorities have 
highlighted the need to completely avoid sodium valproate 
(VPA) in pregnant women and women of childbearing age 
(WOCBA; unless there is no other effective treatment avail-
able) due to convincing evidence of high rates of congenital 
malformations (approximately 11%) [3] and neurodevel-
opmental impairment (30–40%) such as delayed physical 
milestones, memory problems, difficulties in speech and lan-
guage, and lower intellectual ability associated with in utero 
exposure [4–11]. In addition, there is compelling evidence 
of an increased risk of autism and autism spectrum disorder 
in children exposed to VPA in utero [12–15].
Due to its poor safety profile in pregnancy, VPA is indi-
cated for epilepsy only in WOCBA who are intolerant of 
or unresponsive to other antiepileptic treatments and who 
are compliant with an effective Pregnancy Prevention Pro-
gramme (PPP) [2]. However, in HIV-infected adults in 
South Africa receiving antiretroviral treatment (ART), VPA 
has been one of two therapeutic options recommended as 
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Key Points 
Despite warnings, valproate use in women of childbear-
ing age (WOCBA) has not changed in the Western Cape 
Province of South Africa over a 3-year period, and 
sodium valproate (VPA) remains the most commonly 
prescribed antiepileptic or mood-stabilising medicine 
among women of childbearing age in the Western Cape 
Province of South Africa.
Over 3 years, approximately 663 pregnancies were 
exposed to VPA, with a steady rise in the num-
ber of exposures each year (n = 204, 214 and 245, 
respectively). Contributing factors to these trends are 
described, including the concerns about drug–drug inter-
actions between antiepileptic/mood-stabilising medicines 
and antiretrovirals.
Despite significant measures that have been taken at 
both a national and provincial level, the implementa-
tion of new approaches to the treatment of epilepsy in 
women are hindered by challenges facing clinicians in a 
resource-limited setting with a high burden of HIV.
through key informant interviews and meetings with senior 
clinicians and policy makers at the provincial level.
2  Methods
We conducted a retrospective review of aggregate popula-
tion-level data. The Provincial Health Data Centre (PHDC) 
in the Western Cape is a health information exchange in 
which all electronic health data are linked via a unique 
patient identifier allocated to all patients seeking care at 
public health facilities in the Western Cape Province [17].
Anonymised, aggregate data extracts were provided by 
the PDHC for a cohort of WOCBA (13–55 years of age) 
over 3 years from January 2015 to December 2017. Preg-
nancies were identified electronically through a series of 
evidences implying pregnancy, categorised by various lev-
els of confidence. These evidences included registration on 
MomConnect (a mobile health messaging service for South 
African mothers); laboratory tests (e.g. rhesus test, preg-
nancy test, syphilis test, Beta HCG test, and pap smear with 
recorded gestational age); outcome-related evidences (e.g. 
birth registration, diagnostic/procedure-related codes indi-
cating a pregnancy outcome, maternal death, maternal dis-
charge summary); electronic admission records for antenatal 
and obstetric ward visits; and the use of pregnancy-related 
medicines (e.g. misoprostol and mifepristone in combina-
tion indicating termination of pregnancy, iron and folate dis-
pensed) [17–19]. Only high-confidence pregnancies were 
included in this analysis.
Antiepileptic drug/mood-stabilising medication (AED/
MSM) use was identified from electronic pharmacy dis-
pensing records and linked to women in the cohort via the 
unique patient identifier. We defined a pre- and intra-preg-
nancy period, which starts at the beginning of the calendar 
year before the year of delivery and ends with delivery. VPA 
exposure during pregnancy was defined as a WOCBA with 
evidence of pregnancy who has at least one prescription of 
VPA dispensed during the pregnancy period. The pregnancy 
period was defined as the estimated pregnancy start date 
to the pregnancy outcome (including pregnancy loss) date. 
Where available, the last menstrual period and reported ges-
tational age based on ultrasound were used to estimate the 
pregnancy period. In the absence of this data, a period of 
280 days prior to birth was considered the pregnancy period 
for a full-term birth. To ensure maximal ascertainment of 
exposure, all women identified as being prescribed valproate 
in pregnancy were included in our analyses even if the preg-
nancy outcome was unknown.
We explicitly decomposed VPA exposures during preg-
nancy into three types, by timing: (1) VPA initiated dur-
ing pregnancy (defined as the first recorded prescription of 
VPA issued during the pregnancy period); (2) VPA switched 
first-line treatment for the management of epilepsy, the other 
being lamotrigine [16]. This is primarily because most other 
antiepileptics have clinically significant drug–drug interac-
tions with ART, affecting the safety and efficacy of both 
antiepileptic and antiretroviral agents. VPA is also indi-
cated for maintenance therapy for bipolar mood disorder, 
and, together with lithium, was until recently considered a 
first-line option in the public sector in South Africa [16]. It 
has also been used for migraine prophylaxis, although VPA-
containing products are not registered for this indication in 
South Africa [1].
Prior to this study, valproate prescribing practices in 
South Africa were undocumented. In December 2015, a 
Dear Health Care Professional Letter (DHCPL) was dissemi-
nated to registered medical practitioners and pharmacists 
in South Africa warning about the high risk of congenital 
anomalies and developmental disorders associated with VPA 
use during pregnancy (See Electronic Supplementary Mate-
rial 1). This study aimed to establish whether this regulatory 
safety alert had any impact on clinical care or prescribing. 
We aimed to assess the extent of VPA use among pregnant 
women and WOCBA seeking care in the public sector in the 
Western Cape Province, South Africa, using linked popula-
tion-level electronic clinical and pharmacy records between 
January 2015 and December 2017, i.e. 1 year before and 
2 years after the December 2015 DHCPL safety alert. We 
explored reasons for ongoing VPA use in the public sector 
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for an alternative during the course of the pregnancy (first 
AED/MS prescription without VPA issued after the esti-
mated pregnancy start date and before the pregnancy out-
come date); and (3) VPA used throughout pregnancy. Data 
on pregnancy exposures were confined to sites where the 
pharmacy electronic management system was present for 
more than 3 months prior to onset of the pregnancy, reduc-
ing the likelihood of a false date of treatment onset in rela-
tion to the pregnancy episode.
HIV infection prevalence in all pregnant women and 
WOCBA was compared with the HIV prevalence of those 
WOCBA and pregnant women exposed to VPA and alter-
native agents, in the Western Cape Province. HIV status 
was categorised as HIV-infected and, collectively, HIV-
uninfected or HIV status unknown. Given the overwhelm-
ing evidence of risk in pregnancy and the incompleteness 
of provincial birth outcomes data, particularly stillbirths 
and congenital anomalies, data on birth outcomes of AED 
and MSM-exposed pregnancies were not systematically 
assessed. Daily dosage information was not available.
Descriptive statistics were used to report proportions 
and percentages of the outcomes. Pearson’s Chi-square test 
was used to compare pregnancy rates among women taking 
VPA compared with women taking other AED and MSM 
regimens, as well as comparing VPA exposure rates among 
women living with and without HIV.
Discussions were held with senior clinicians and policy 
makers at the provincial level, including pharmacologists, 
neurologists, psychiatrists, pharmacists and fetal medicine 
specialists, to understand the determinants of VPA use in 
the Western Cape Province. The aim of these discussions 
was to identify opportunities to reduce pregnancy exposures 
to VPA and to develop systems aimed at better supporting 
pregnant women and their infants exposed to VPA in utero. 
The key findings and recommendations of these meetings 
are also presented.
Approval for the study was granted by the University of 
Cape Town Faculty of Health Sciences Human Research 
Ethics Committee (ref: 098/2018) and the Western Cape 
Provincial Research Committee. The data that support the 
findings of this study are available from the PHDC, but 
restrictions apply to the accessibility of these data, which 
were used after approval for the current study, and are there-
fore not publicly available. Data are however available from 
the authors upon reasonable request and with permission of 
the Western Cape Provincial Research Committee.
3  Results
Approximately 1 million WOCBA seek care every year from 
a provincial health facility in the Western Cape, with HIV 
infection rates ranging from 17.2–19.3% per year over the 
course of the study period (Table 1). Over the 3 years, at 
least one VPA prescription was dispensed to between 0.79% 
and 0.94% of these WOCBA . In all 3 years, prescriptions 
for VPA were significantly more likely in HIV-infected 
WOCBA and pregnant women compared with HIV-negative 
women or women for whom HIV status was undocumented 
(p < 0.001) (Table 1). VPA prescriptions for WOCBP or 
pregnant women did not significantly decrease after the 
DHPCL. The data concerningly suggest no difference, or 
possibly an upward trend, in prescribing after the DHCP 
letter (Table 1).
Valproate was the most prescribed AED or MSM among 
WOCBA (43.2–45.5% of treated WOCBA per annum irre-
spective of HIV infection status) during the study period. 
Lamotrigine, the other recommended first-line agent, was 
only prescribed in 7.8–8.9% of all WOCBA using an AED 
or MSM (Table 2). Carbamazepine (22.6–25.7%), risperi-
done (21.9–24%) and phenytoin (14.8–19.3%) were the most 
commonly used alternatives to VPA for epilepsy and mood 
disorder, respectively.
Over the course of 3 years, 663 pregnancies were exposed 
to VPA, with a progressively increasing absolute number of 
exposed pregnancies each year (Table 3). Based on Inter-
national Classification of Diseases (ICD) coding of health 
facility visits, the indication in most cases was neurological 
(79–81%) and was therefore likely to represent the manage-
ment of epilepsy or other seizure disorders. Overall, 121 
women initiated, and 87 women discontinued, VPA during 
pregnancy over the 3-year period. Of those women who were 
exposed to VPA during the year of their pregnancy, VPA 
was stopped prior to the estimated onset of the pregnancy in 
55.5–63.9% of women (Table 4). There was no increase in 
the number of women discontinuing valproate preconceptu-
ally following the DHCPL. The use of the alternative agent 
lamotrigine remained consistent across the 3-year period.
The overall pregnancy rate in women taking AEDs and 
MSMs was significantly lower compared with the total pro-
vincial cohort of WOCBA (5.9% vs. 10.3%; p < 0.001). 
There were no marked differences in pregnancy rates among 
women taking VPA-containing AEDs/MSMs compared with 
non-VPA containing AEDs/MSMs, although pregnancy 
rates did drop from 2015 to 2016 (6.6% to 5.6%; p < 0.001), 
but not from 2016 to 2017 in women taking any AED/MSM 
(5.6–5.4%; p = 0.350) [Table 5].
We did not assess the impact of VPA pregnancy expo-
sures on birth outcomes because of the incomplete electronic 
record linkage between infants and mothers, unreliable ICD 
coding of congenital malformations, and other adverse birth 
outcomes.
Discussions were held with senior neurologists, psychia-
trists, members of the provincial pharmacy and therapeu-
tics committee, and clinical pharmacologists in the Western 
Cape Province to determine the reason for such widespread 
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use of VPA among WOCBA. Table 6 summarises the key 
reasons identified.
4  Discussion
This analysis of prescription practices from 2015 to 2017, 
derived from population-level data, indicates that despite 
the known significant risks that VPA poses to the foetus, 
it remained the most frequently prescribed AED/MSM in 
WOCBA and pregnant women in public health facilities 
in the Western Cape Province. Over 3 years, VPA use in 
WOCBA and pregnant women did not decrease, despite 
nationwide dissemination of a DHCPL by its manufactur-
ers in December 2015. Up to 245 women per year (Table 3) 
were exposed to VPA during the course of their pregnancy 
in this province alone.
Based on the electronic record of the prescribing clini-
cal specialty, it appears that VPA’s primary use is in the 
management of epilepsy and possibly other neurological 
conditions. Women with bipolar mood disorder also con-
tinue to be prescribed VPA despite international consen-
sus on the need to reduce the use of this agent for mood 
disorders in WOCBP [1, 2, 21–30]. This may be because 
there are also concerns about the safety of lithium therapy 
in pregnancy, both in terms of challenges in optimal dosing 
during pregnancy and concerns about the risk of Ebstein’s 
Table 1  Valproate use in 
women of childbearing age and 
pregnant women, by HIV status






 Number of WOCBA taking VPA (%) 6208 (0.72) 1997 (1.11) 8205 (0.79) <0.001
 Total number of WOCBA 864,222 180,599 1,044,821
2016
 Number of WOCBA taking VPA (%) 6957 (0.86) 2468 (1.28) 9425 (0.94) < 0.001
 Total number of WOCBA 812,401 193,446 1,005,847
2017
 Number of WOCBA taking VPA (%) 7145 (0.81) 2757 (1.31) 9902 (0.91) <  0.001
 Total number of WOCBA 880,667 211,051 1,091,718
Pregnancies while taking VPA
2015
 Number of pregnant women
 taking VPA (%)
125 (0.15) 79 (0.56) 204 (0.21) < 0.001
 Total number of pregnancies 84,697 14,131 98,828
2016
 Number of pregnant women taking VPA (%) 152 (0.18) 62 (0.41) 214 (0.21) < 0.001
 Total number of pregnancies 86,360 15,174 101,534
2017
 Number of pregnant women taking VPA (%) 149 (0.16) 96 (0.53) 245 (0.22) < 0.001
 Total number of pregnancies 92,861 18,067 110,928
Table 2  Use of antiepileptic drugs and mood-stabilising medicines in 
women of childbearing age
AEDs antiepileptic drugs, MSMs mood-stabilising medicines, 
WOCBA women of childbearing age
a Many women were exposed to more than one AED or MSM, either 
concurrently or consecutively, during the course of each year
b Percentage of all WOCBA taking either an AED or an MSM
c Percentage of all WOCBA
AED or MSM used 2015a (%)b 2016a (%)b 2017a (%)b
Sodium valproate 8205 (43.2) 9425 (45.5) 9902 (44.8)
Carbamazepine 4874 (25.7) 4930 (23.8) 5001 (22.6)
Risperidone 4162 (21.9) 4906 (23.7) 5308 (24.0)
Phenytoin 3653 (19.3) 3505 (16.9) 3284 (14.8)
Lamotrigine 1482 (7.8) 1673 (8.1) 1962 (8.9)
Olanzapine 992 (5.2) 1374 (6.6) 1813 (8.2)
Lithium 903 (4.8) 1024 (4.9) 1042 (4.7)
Levetiracetam 64 (0.8) 65 (0.3) 88 (0.4)
Total number of 
WOCBA taking 
AEDs or MSMs 
(%)
18,974 (1.82c) 20,701 (2.06c) 22,120 (2.03c)
Total number of 
WOCBA not 
taking AEDs or 
MSMs
1,025,847 985,147 1,069,598
Total number of 
WOCBA
1,044,821 1,005,847 1,091,718
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anomaly (albeit much rarer than VPA-associated fetal com-
plications) [31]. Despite recent reports suggesting that the 
teratogenic risk of lithium is dose-related and much lower 
than previously hypothesised [31], the exaggerated percep-
tion of lithium’s teratogenic risks may have contributed to 
a preference for VPA over lithium. Similar trends of high 
Table 3  Sodium valproate use 
in pregnancy, by clinical service 
accessed
VPA sodium valproate
a Mental health service, or both neurology and mental health services, accessed by the patient
Year pregnancy ended
2015 (%) 2016 (%) 2017 (%)
Neurology service only 161 (79) 182 (85) 199 (81)
Mental health service only, or  botha 43 (21) 32 (15) 46 (19)
Total number of pregnancies exposed to VPA 204 214 245
Table 4  Prescribing of AED/MSM in the pre- and intra-pregnancy  perioda
VPA sodium valproate, AED antiepileptic drug, MSM mood-stabilising medication
a The pre- and intra-pregnancy period starts at the beginning of the calendar year before the year of delivery, and ends with delivery
b Exposures to any AED/MSM are not exclusive
Year pregnancy ended
2015 (%) 2016 (%) 2017 (%)
Total number of women exposed to any AED/MSM 1260 1161 1195
Number of women exposed to  lamotrigineb (% of exposure to AED/MSM) 116 (9) 105 (9) 104 (9)
Number of women exposed to  VPAb (% of exposure to AED/MSM) 566 (45) 544 (47) 551 (46)
VPA stopped before pregnancy (% of women exposed to VPA) 362 (64) 330 (61) 306 (56)
Pregnancy exposed to VPA (% of women exposed to VPA) 204 (36) 214 (39) 245 (44)
 Exposed throughout pregnancy (% of pregnancies
 exposed)
132 (65) 149 (70) 174 (71)
 Initiated during  pregnancyb (% of pregnancies exposed) 42 (21) 37 (17) 42 (17)
 Switched off during pregnancy (% of pregnancies exposed) 30 (15) 28 (13) 29 (12)
Table 5  Proportion of women of childbearing age who received antiepileptic drugs or mood-stabilising medicines in the year of conception
WOCBA women of childbearing age, AEDs antiepileptic drugs, MSMs mood-stabilising medications, VPA sodium valproate
a Dear Health Care Professional Letter on sodium valproate safety in pregnancy was issued in December 2015
b Were receiving AEDs/MSMs prior to conception
Year pregnancy ended
2015 % 2016a % 2017 %
Total number of WOCBA receiving AEDs and MSMs 18,974 20,701 22,120
Number of women receiving any AED/MSM in the year of  conceptionb 1260 6.6 1161 5.6 1195 5.4
Total number of WOCBA receiving VPA 8205 9425 9902
Number of women receiving VPA in the year of conception 566 6.9 544 5.8 551 5.6
Total number of WOCBA receiving non-VPA AEDs and MSMs 10,769 11,276 12,218
Number of women receiving non-VPA AEDs or MSMs in the year of conception 694 6.4 617 5.5 644 5.3
Total number of WOCBA accessing care at a health facility 1,044,821 1,005,847 1,091,718
Number of WOCBA who had a pregnancy 101,865 9.7 105,286 10.5 114,837 10.5
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rates of valproate use have been noted in other countries [32, 
33]. Shorter and less continuous VPA prescribing patterns 
for non-epileptic indications, such as bipolar mood disorder, 
could explain the more limited teratovigilance research in 
the psychiatric literature. This could have further contributed 
to lower awareness of these risks among clinicians involved 
in the care of patients with non-epileptic disorders [32].
We found that the prescribing rates of VPA in WOCBA 
were higher among HIV-infected versus HIV-uninfected 
women. This is probably because the older South Afri-
can national treatment guidelines recommended VPA and 
lamotrigine as first-line treatments for epilepsy and mood 
disorders in women receiving ART, driven by concerns of 
pharmacokinetic interactions between AEDs and antiret-
roviral agents (including dolutegravir, which has recently 
been introduced as part of first-line HIV treatment in South 
Africa) [20, 34]. Although lamotrigine is the other recom-
mended agent for WOCBA and pregnant women, the com-
plicated initiation regimen, the need for intensive therapeutic 
drug monitoring particularly during the pregnancy and after 
delivery [35], and concerns regarding the risk of severe skin 
reactions, has contributed to the preferential prescribing of 
VPA in this population. Only 9% of women who experienced 
a pregnancy in that year and who were taking any type of 
AED/MSM were exposed to lamotrigine, compared with 
45–47% who were exposed to VPA (Table 4).
In resource-constrained health care settings, rational and 
safe prescribing of medicines is challenging for multiple 
reasons: access to specialist services are limited; medicines 
formularies are often confined to the most cost-effective 
options; medicine stock-outs are commonplace; and refer-
ral linkage between clinical services (e.g. between neurology 
and family planning) may be suboptimal. The prescribing of 
risky or suboptimal treatments in challenging patient sub-
groups can occur despite the presence of safer alternatives 
on the market.
The pregnancy rate of WOCBA taking AEDs and MSMs 
was significantly lower than the pregnancy rate of WOCBA 
not taking these agents, suggesting that either women tend 
to be aware of the risks of taking AEDs/MSMs in pregnancy, 
or the underlying condition directly or indirectly impacts fer-
tility. As contraceptive use is not routinely recorded on the 
provincial electronic platform, we were unable to compare 
contraceptive use among WOCBA in the different treatment 
groups.
This analysis has demonstrated the value of the linked 
population-level data in identifying problematic prescribing 
practices in high-risk groups. A validation study previously 
conducted on the quality of exposure data comparing clinical 
maternity records with the electronic pharmacy system has 
demonstrated that chronic medications are reliably recorded 
Table 6  Reasons cited by key informants on the widespread use of sodium valproate in women of childbearing age and pregnant women
VPA sodium valproate, AED antiepileptic drug, ART antiretroviral therapy
a Known interactions between efavirenz and carbamazepine, phenytoin and phenobarbital, through cytochrome P450 system induction. VPA has 
no inducing effects on ART metabolism but has been shown to displace protein binding of the antiretroviral dolutegravir, which is not clinically 
important as it does not change the free, active dolutegravir concentrations. Levetiracetam is not metabolised by the cytochrome P450 system as 
it is eliminated unchanged in the urine after undergoing enzymatic hydrolysis [20]
1. VPA and lamotrigine are very effective treatments for both focal and generalised forms of epilepsy, and represent a valuable therapeutic 
option for both epilepsy and mood disorder patients
2. VPA and lamotrigine have a better drug interaction profile compared with phenytoin and carbamazepine, and hence are safer to use in 
HIV-infected patients receiving antiretroviral  therapya
3. Lamotrigine requires more intensive clinical management as it must be titrated slowly (6–7 weeks) to the therapeutic dosage to reduce 
the likelihood of serious skin reactions. This increases the burden on the healthcare system by increasing patient visits with limited spe-
cialist and therapeutic monitoring resources
4. Any interruption in therapy (i.e. in the case of non-compliance or in the event of stock-outs) requires lamotrigine titration to be re-
initiated, resulting in a risk of breakthrough seizures as well as the need for additional treatment, facility visits and monitoring
5. The impact of switching treatment on quality of life and seizure control in epilepsy patients is significant—a patient is not allowed to 
drive or operate heavy machinery for 1 year after any treatment switch, even if the patient has remained seizure-free. In addition, during 
the switchover period, there may be a greater risk of breakthrough seizures, which are also associated with risks to both the mother and 
the foetus
6. Mood disorder patients are often non-adherent, and concerns were raised about the mood-stabilising effects of alternative agents avail-
able in the public sector in South Africa, including antipsychotics and lithium
7. Lithium use for mood disorders in pregnancy is also challenging given its narrow therapeutic range, and hence the need for careful dose 
titration and monitoring during pregnancy and the increased perceived risk of congenital disorders such as Ebstein’s anomaly following 
in utero exposure
8. At the time of these consultations, access to the safer alternative AED, levetiracetam, was restricted to specialist use at tertiary hospitals 
due to prohibitive costs
9. Information on the performance of levetiracetam in South African patients is limited. Referral links between neurology and psychiatry, 
and women’s health services such as family planning and antenatal care are not always optimal and could be strengthened. This is to 
ensure that women receive adequate family planning and utilise effective contraception when prescribed VPA
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and accessible in the electronic pharmacy management sys-
tem compared with paper-based records [36].
This investigation identified special challenges typical 
of low- to middle-income settings, such as limited access 
to alternative treatment options due to prohibitive costs, 
and the lack of easily accessible local data to motivate for 
revision of treatment guidelines. Moreover, in the absence 
of widespread and intensive advocacy efforts, the DHCPL 
alone did not appear to improve VPA prescribing patterns.
Levetiracetam is recognised as an alternative with a lower 
risk of congenital malformations, as well as a low risk of 
drug–drug interactions with other medications, includ-
ing antiretrovirals [37]. However, due to the significantly 
increased cost and the risk of neuropsychiatric adverse 
effects (depression, aggression, suicidality and psychosis) 
[38], access to this alternative treatment has been limited to 
higher levels of care. In the Western Cape province, where 
data on high rates of VPA exposure in pregnancy were made 
available to the Provincial Pharmacy and Therapeutics Com-
mittee, the coding status of levetiracetam was amended in 
2019. As a result, levetiracetam may be initiated by certain 
clinicians (specialist family physicians, neurologists, psy-
chiatrists, paediatricians, neurosurgeons and physicians) 
and is now more easily available as a treatment option for 
women receiving ART and women who were previously 
taking VPA. In both these situations, lamotrigine would be 
recommended as the first choice and levetiracetam would be 
reserved for women who are intolerant or unresponsive to 
lamotrigine. At a national level, discussions are being held 
within the Essential Medicines Programme on the critical 
need and feasibility of including additional treatment options 
for epilepsy and mood disorders in the public sector. Until 
more practical alternatives are available to prescribers in 
the public sector, first-line use of lamotrigine for the treat-
ment of epilepsy is being encouraged. International data sug-
gest that local training initiatives aimed at educating doc-
tors, pharmacists and patients on the risks of VPA should 
be developed [26]. Similar reluctance among health care 
providers to change prescribing practices, and challenges 
encountered in communicating these risks to patients, has 
been repeatedly described in other settings [26, 29, 30, 39, 
40].
Decision making around the prescription of valproate 
and other antiepileptics in pregnant women and WOCBA 
is complex and involves the consideration of multiple fac-
tors. The reproductive risks of VPA have to be weighed 
against the need for optimal seizure control. Early reports 
of the SANAD II study suggest that levetiracetam may be 
an inferior antiepileptic to VPA [41], while Angus-Leppan 
and colleagues found that between 33 and 43% of clinicians 
surveyed in the UK noted deterioration in among women 
who were switched from VPA to an alternative agent [42]. 
The risks of inadequate seizure control during pregnancy, 
both to the woman and the foetus, are significant and include 
maternal death, sudden unexpected death, small for gesta-
tional age, and preterm delivery [43].
Women need to be provided with up-to-date informa-
tion on the risks and benefits of various treatment options, 
including the risks of switching therapy, in order to make 
informed decisions. While the implementation of the PPP 
will provide clinicians with a framework for engaging 
women in informed decision making around the use of val-
proate in pregnancy, it may not adequately provide women 
with information on the potential risks of switching therapy. 
Moreover, women with learning disabilities may be unable 
to engage with the informed consent process required by the 
PPP [44]. Therefore, the impact of these regulatory warnings 
and revised treatment guidelines will need to be monitored 
more holistically through prescribing trends, indicators of 
seizure control, and rates of adverse maternal and pregnancy 
outcomes.
The shortcomings of the DHCPL as a regulatory risk 
communication tool has been highlighted by others [45–47]. 
Therefore, the apparent lack of response in valproate pre-
scribing patterns, despite the dissemination of the DHCPL, 
has highlighted the need for improved risk communication 
strategies by regulatory authorities. Regulators and pharma-
ceutical manufacturers must assess the clinical value of the 
DHCPL and explore additional, more accessible, clinically 
relevant approaches to communicating risk, particularly in 
resource-limited settings.
This study had several limitations. The PHDC consoli-
dates electronic data sources and dispensing data were lim-
ited to those facilities with an electronic pharmacy man-
agement system, and, as such, the dispensing data may be 
incomplete. However, AEDs and MSMs are most commonly 
dispensed from referral facilities and, in the Western Cape, it 
is only primary health care clinic sites that are not digitised.
Drug exposures were based on prescriptions dispensed in 
relation to the estimated onset of pregnancy. In the absence 
of clinical evidence of gestational age (i.e. expected date of 
delivery by ultrasound, last menstrual period and symphysis 
fundal height), this was determined using birth weight and 
date of delivery. Therefore, pregnancy exposures are esti-
mated in some cases. The timing of exposure during preg-
nancy may be problematic given the sparse data recorded 
electronically on which to estimate the gestational dating of 
the exposures. This is a common challenge encountered by 
others [48]. In the case of well-described teratogens such as 
VPA, the absence of reliable local outcome data does not 
diminish the value of determining the extent of exposure. In 
Europe, prescribing patterns monitored over a longer period 
of 14 years have noted pronounced changes in VPA prescrib-
ing and, consequently, significant reductions in teratogenic 
events [49].
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Only pregnancies with evidence in the PHDC were 
included; thus, importantly, pregnancies that ended in mis-
carriage prior to an antenatal visit were not included.
Pharmacy data in the PHDC represents dispensing data 
and we cannot be certain that these medicines were taken 
as prescribed, only that they were collected; nor could we 
assess whether advice on contraception was provided or 
adhered to. The indications for use of these medicines in 
each patient are not routinely captured in the electronic phar-
macy system, and diagnostic codes are not reliably captured 
province-wide to allow for analysis of VPA use in WOCBA 
and pregnant women by indication. We had to rely on the 
crude indicator of clinical service accessed by the patient to 
differentiate whether VPA was being used for a psychiatric 
versus neurological indication (Table 3).
The findings were only based on data from one prov-
ince of South Africa, where electronic patient registers and 
record linkage facilitated the analysis. In other provinces, 
HIV prevalence rates among WOCBA and pregnant women 
are much higher (up to 44.4%, compared with 19.3% in our 
cohort), likely resulting in higher rates of VPA prescribing 
in order to avoid interactions with ART [50].
The dialogue initiated in response to the high rates of 
VPA prescribing in WOCBA resulted in formal action at 
both the national and provincial levels.
Provincial level Within the Western Cape Province, sev-
eral steps were taken to reduce VPA use in WOCBA. These 
included:
1. Increasing access to safer alternatives such as lamotrig-
ine, clobazam (as a temporary adjunct agent to provide 
cover during the slow dose-escalation phase when lamo-
trigine is initiated), and levetiracetam. In the case of the 
latter, this involved reducing the guideline restrictions 
for both prescriber and patient. Only the lower dose of 
levetiracetam 250 mg is procured to facilitate ease of 
dose titration and adjustment.
2. Training of designated prescribers of lamotrigine by dis-
trict clinical specialists on the adverse effects of avail-
able AEDs, and a titration regimen for helping women 
transition from VPA to lamotrigine.
3. Providing a provincial clinical guideline to all heads 
of clinical neurology and psychiatry units on the most 
appropriate use of AEDs and MSMs in adolescent and 
adult WOCBA for both epilepsy and bipolar mood dis-
order.
4. Distribution of an Acknowledgement of Risk form for 
completion by all prescribers and women initiated on 
VPA, and again annually thereafter.
To monitor trends in VPA prescribing in the province, a 
set of key indicators were developed that could be provided 
to the provincial Pharmacy and Therapeutics Committee, on 
a regular basis, by the PHDC to assess the impact of these 
measures on VPA prescribing in WOCBA.
As is already a mainstay of practice for other clini-
cal scenarios in the province, an automated notification 
system is being envisioned whereby the PHDC is able 
to notify the facility of any pregnancies with identified 
teratogenic exposures so that these women can be referred 
for relevant clinical specialist services. The clinical genet-
ics unit will serve as a referral point for all VPA-exposed 
infants so that these infants can be properly assessed, their 
parents counselled, and the children can receive appropri-
ate access to relevant long-term care such as occupational 
therapy, if required.
National level In 2018, VPA use was continued by the 
National Essential Medicines List Committee (NEMLC) 
as first-line use in children on the condition that, in girls, 
treatment be switched to an alternate anticonvulsant when 
they reached childbearing age. Similarly, VPA was con-
traindicated in WOCBA unless alternate treatment could 
not be used, in which case reliable contraception was 
required [51]. The NEMLC, appointed by the Minister 
of Health, is responsible for formulating and revising the 
National List of Essential Medicines based on clinical 
need, evidence of efficacy, quality, safety, affordability 
and implications for practice. The SAHPRA required 
VPA manufacturers to support a PPP. This will enable 
programmatic units to be guided on how to implement 
measures aimed at reducing pregnancy exposures to VPA 
in the public sector.
5  Conclusions
Our analysis of VPA prescribing practice in WOCBA using 
population-level provincial data identified potentially unsafe 
practices. In response, stakeholder discussions explored a 
response to therapeutic challenges in the context of AED and 
MSM use in pregnant women and WOCBA in South Africa. 
The investigation has highlighted how, in this resource-con-
strained setting with a high burden of HIV-infected women 
taking antiretroviral therapy, lack of awareness of the extent 
of the problem in the local setting, and the high cost of and 
consequent poor access to alternative medicines and spe-
cialised care can contribute to the continued use of poten-
tially harmful treatments in WOCBA. Within this context, 
the DHCPL disseminated by the manufacturers appears not 
to have any significant impact on valproate prescribing in 
WOCBA.
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